23 reports

Gliptins Sodium-Glucose Co-Transporter ## Inhibitor

  • Antidiabetics
  • World
  • APAC
  • North America
  • Europe
  • Health Expenditure
  • Diabetes Prevalence

Canada Diabetes Care Insulin Biguanide Gliptins Diabetes Hospital

  • Insulin
  • Insulin Delivery
  • Diabetes Care
  • Diabetes Monitoring
  • Canada
  • Diabetes Prevalence
  • Drug Approval

This report was created for global strategic planners who cannot be content with traditional methods of segmenting world markets. With the advent of a "borderless world", cities become a more important criteria in prioritizing markets, as opposed to regions, continents, or countries. This report covers the top 2,000 cities in over 200 countries....

  • Antidiabetics
  • Diabetes
  • Insulin
  • Biguanide
  • Alpha-Glucosidase Inhibitor
  • Packaging
  • World
  • Diabetes Medicine Sales

According to a research study published by researchers at the Sunnybrook Research Institute and the University of Toronto in Alzheimer's & Dementia: The Journal of the Alzheimer's Association (July 2020), it was found that an anti-diabetic drug, dipeptidyl peptidase-## (DPP##) inhibitor, may have the potential to slow memory loss in patients with Alzheimer's disease.

  • Dementia
  • Therapy
  • Pharmaceutical
  • APAC
  • Europe
  • South America
  • Dementia Prevalence
  • Elderly Population

• The global market for enzyme inhibitors should reach $179.9 billion by 2022 from $168 billion in 2017 at a compound annual growth rate (CAGR) of 1.4%, from 2017 to 2022. • The kinase inhibitors market is expected to grow from $54.9 billion in 2017 to $80 billion in 2022 at a CAGR of 7.8% for the period 2017-2022. • The reverse transcriptase...

  • Antiviral
  • Targeted Therapy
  • Lipid Modifying Drug
  • HIV AIDS
  • World
  • United States

BETonMACE Endpoints w ith Oral Anti-Diabetic Treatments Including SGLT## or DPP## Inhibitors: Primary MACE ( CV death, non-f atal MI and stroke): ## percent Hazard reduction (HR, ##; ## percent CI, ##-##; p-value equal to ##), primary MACE including Hospitalization f or Congestive Heart Failure (CHF): ## percent Hazard reduction (HR, ##; ## percent CI, ##- ##; p-value equal to ##) and hospitalization for CHF: ## percent Hazard reduction (HR, ##; ## percent CI, ##-##; p-value equal to ##).

  • Neurological Disorder
  • Therapy
  • World
  • South Africa
  • Number Of R&D Personnel
  • Drug Approval

BETonMACE Endpoints w ith Oral Anti-Diabetic Treatments Including SGLT## or DPP## Inhibitors: Primary MACE ( CV death, non-f atal MI and stroke): ## percent Hazard reduction (HR, ##; ## percent CI, ##-##; p-value equal to ##), primary MACE including Hospitalization f or Congestive Heart Failure (CHF): ## percent Hazard reduction (HR, ##; ## percent CI, ##- ##; p-value equal to ##) and hospitalization for CHF: ## percent Hazard reduction (HR, ##; ## percent CI, ##-##; p-value equal to ##).

  • Therapy
  • Pharmaceutical
  • World
  • Prescription Drug Sales
  • Hospital Admission

BETonMACE Endpoints w ith Oral Anti-Diabetic Treatments Including SGLT## or DPP## Inhibitors: Primary MACE ( CV death, non-f atal MI and stroke): ## percent Hazard reduction (HR, ##; ## percent CI, ##-##; p-value equal to ##), primary MACE including Hospitalization f or Congestive Heart Failure (CHF): ## percent Hazard reduction (HR, ##; ## percent CI, ##- ##; p-value equal to ##) and hospitalization for CHF: ## percent Hazard reduction (HR, ##; ## percent CI, ##-##; p-value equal to ##).

  • Cardiovascular Disease
  • Therapy
  • World
  • Mortality Rate
  • Hospital Discharge

DPP## Inhibitors

  • Therapy
  • Clinical Trial
  • United States
  • Overweight Prevalence
  • Sugar Consumption

BETonMACE Endpoints with Oral Anti-Diabetic Treatments Including SGLT## or DPP## Inhibitors: Primary MACE (CV death, non-fatal MI and stroke): ## percent Hazard reduction (HR, ##; ## percent CI, ##-##; p-value equal to ##), primary MACE including Hospitalization for Congestive Heart Failure (CHF): ## percent Hazard reduction (HR, ##; ## percent CI, ##- ##; p-value equal to ##) and hospitalization for CHF: ## percent Hazard reduction (HR, ##; ## percent CI, ##-##; p-value equal to ##).

  • Cancer
  • Therapy
  • Drug Development
  • Oncology
  • Oncology
  • Biopharmaceutical
  • World
  • Pharmaceutical Registrations
  • Drug Approval

Diabetes Therapeutics Market by Product [Injectables (Insulin, Glucagon-like Peptide-1 (GLP-1) Receptor Agonists, and Amylinomimetic Drugs) and Oral-antidiabetic Drugs (OAD) (Biguanides, Sulfonylureas, Thiazolidinediones, Alpha-glucosidase Inhibitors, Dipeptidyl Peptidase IV (DPP-4) Inhibitors, Meglitinides, and Sodium-glucose Cotransporter-2...

  • Antidiabetics
  • Diabetes
  • World
  • Diabetes Prevalence

BETonMACE Endpoints with Oral Anti-Diabetic Treatments Including SGLT## or DPP## Inhibitors: Primary MACE (CV death, non-fatal MI and stroke): ## percent Hazard reduction (HR, ##; ## percent CI, ##-##; p-value equal to ##), primary MACE including Hospitalization for Congestive Heart Failure (CHF): ## percent Hazard reduction (HR, ##; ## percent CI, ##- ##; p-value equal to ##) and hospitalization for CHF: ## percent Hazard reduction (HR, ##; ## percent CI, ##-##; p-value equal to ##).

  • Drug Development
  • Therapy
  • Pharmaceutical
  • World
  • Prescription Drug Sales
  • Hospital Admission

Hepatitis Treatment Antiviral Hospital Healthcare Acne Treatment Lipid Modifying Drug Biguanide Asthma Gliptins Sodium-Glucose Co-Transporter ## Inhibitor Statins Pharmacy

  • Healthcare
  • HIV Antiviral
  • Antipsychotic
  • Spain
  • World
  • Direct Sales
  • Pharmacy Sales

Taiwan South Korea United States Sodium-Glucose Co-Transporter ## Inhibitor Therapy Gliptins

  • Therapy
  • World
  • Southeast Asia
  • Drug Approval
  • Inflation Rate

Belgium Hepatitis Treatment Opioid Pharmaceutical Analgesic Healthcare Acne Treatment Respiratory Treatment Cardiology Pharmacy Interferon Influenza Asthma Gliptins Hormone Statins

  • Healthcare
  • Analgesic
  • Opioid
  • Belgium
  • World
  • Direct Sales
  • Pharmacy Sales

Japan Renal Disease Pharmaceutical Gliptins

  • Insulin
  • World
  • United States
  • Diabetes Prevalence
  • Drug Approval

It is a gliptin class of anti-diabetic agents.

  • Vaccine
  • Infectious Disease
  • Therapy
  • World
  • Yamagata Prefecture
  • Pharmaceutical Registrations
  • Drug Approval

Can top-ranked GLP1 agonists move out of the third-line setting? GLP1 agonists may be the top-ranked type 2 diabetes mellitus (T2DM) treatment according to the American Association of Clinical Endocrinologists (AACE), but physicians pushing to move them up the treatment...

  • Insulin
  • Type 2 Diabetes
  • World
  • Europe
  • European Union
  • North America
  • United States
  • Catalonia

In 2003, PPD entered into a collaboration agreement to develop Syrrx s orally active DPP## inhibitors to treat type ## diabetes and other major human diseases.

  • Therapy
  • Monoclonal Antibody
  • Vaccine
  • Infectious Disease
  • Cardiovascular Drug
  • Oncology
  • United States
  • Japan
  • Diagnostic Imaging Density
  • Drug Approval

Laboratoires Pierre Fabre France Gliptins

  • Pharmaceutical
  • Biopharmaceutical
  • Oncology
  • Clinical Trial
  • Private Placement
  • Beta-Blocker
  • France
  • King County
  • Nouvelle-Aquitaine
  • Dates Price
  • Manufacturing Output

Saxagliptin is a dipeptidyl peptidase-## (DPP##) inhibitor and dapagliflozin is a sodium glucose co-transporter ## (SGLT##) inhibitor.

  • Therapy
  • Pharmaceutical
  • Pathology
  • Cancer
  • Hospital
  • Oncology
  • Anti-Infective
  • Respiratory Treatment
  • United States
  • World
  • North America
  • Drug Approval
  • Food Consumption

"We are delighted to note that so far our clinical data strongly support this clinical profile, with no notable adverse effects, thus underscoring AZP-##'s significant clinical and commercial potential as an add-on therapy, especially in combination with leading insulin secretagogues (GLP-## agonists and DPP## inhibitors)."

  • Hormone
  • Pharmaceutical
  • World
  • Energy Consumption
  • Pharmaceutical Registrations

He explained how the AIFA monitored treatment use, duration, cost, and resulting blood sugar levels among several tens of thousands of patients taking seven diabetes drugs, including five gliptins and the glucagon-like peptide-## (GLP-##) agonists Byetta (exenatide; Bristol-Myers Squibb/AstraZeneca) and Victoza (liraglutide; Novo Nordisk).

  • Pharmaceutical
  • Healthcare
  • Respiratory Treatment
  • United States
  • Italy
  • Medical Technology Density
  • Number Of Enterprises